nach oben

Erschienen in:

10.07.2023 | Original Article

Can a novel drug dose be used for T3 suppression test?

verfasst von: Sedat Çetin, Mehmet Güven, Başak Bolayır, Mehmet Şimşek, Hikmet Soylu, Dilek Geneş, Nurettin Ay, Halit Diri

Erschienen in: Endocrine | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to investigate whether 25 µg/day dose of triiodothyronine (T3) can also suppress thyroid stimulating hormone (TSH) level, as well as the routine dose of 50–100 µg/day in T3 suppression test, which is used to the distinguish between resistance to thyroid hormone (RTH) and TSH secreting pituitary adenoma.

Methods

In this prospective study, 26 patients with genetically proven RTH were randomly divided into two groups: Group 1 comprised 13 patients who were administered 50–100 µg/day T3 for 3–9 days, while Group 2 also comprised 13 patients who were administered 25 µg/day T3 for 7 days for T3 suppression test. The two groups’ responses to T3 suppression tests were compared.

Results

The comparison of the mean percentage changes in TSH values by the T3 suppression tests showed no significant differences between the groups, and a ≥80% decrease was detected in all patients. Nine patients in Group 1 and one patient in Group 2 reported that they had to use propranolol due to tachycardia developed during the test.

Conclusion

As higher doses of T3 can increase the risk of severe tachycardia during T3 suppression test, a low dose with 25 mcg/day for a week appears to be safer and more useful.

T. Pappa, S. Refetoff, Resistance to thyroid hormone beta: a focused review. Front. Endocrinol. (Lausanne) 12, 656551 (2021). https://doi.org/10.3389/fendo.2021.656551CrossRefPubMed

A. Vela, G. Perez-Nanclares, I. Rios, I. Rica, N. Portillo, L. Castano; Spanish Group for the Study of, R.T.H., Thyroid hormone resistance from newborns to adults: a Spanish experience. J. Endocrinol. Invest. 42(8), 941–949 (2019). https://doi.org/10.1007/s40618-019-1007-4CrossRefPubMed

S.H. Lafranchi, D.B. Snyder, D.E. Sesser, M.R. Skeels, N. Singh, G.A. Brent, J.C. Nelson, Follow-up of newborns with elevated screening T4 concentrations. J. Pediatr. 143(3), 296–301 (2003). https://doi.org/10.1067/S0022-3476(03)00184-7CrossRefPubMed

P. Beck-Peccoz, C. Giavoli, A. Lania, A 2019 update on TSH-secreting pituitary adenomas. J. Endocrinol. Invest. 42(12), 1401–1406 (2019). https://doi.org/10.1007/s40618-019-01066-xCrossRefPubMed

J.G. Timmons, B. Mukhopadhyay, Hyperthyroxinemia with a non-suppressed TSH: how to confidently reach a diagnosis in this clinical conundrum. Hormones (Athens) 19(3), 311–315 (2020). https://doi.org/10.1007/s42000-020-00180-3CrossRefPubMed

C. Chiang, I.W., M. Grossmann, R. Clifton-Bligh, P. Coates, E.M. Lim, P. Ward, P. Stanford, C. Florkowski. D.J.: 8.2 T3 SUPPRESSION TEST. ESA - Guidelines - Endocrine Society of Australia. https://www.endocrinesociety.org.au/guidelines.asp#hedta. (2021). Accessed 2021

E. Macchia, M. Lombardi, V. Raffaelli, P. Piaggi, L. Macchia, I. Scattina, E. Martino, Clinical and genetic characteristics of a large monocentric series of patients affected by thyroid hormone (Th) resistance and suggestions for differential diagnosis in patients without mutation of Th receptor beta. Clin. Endocrinol. (Oxf) 81(6), 921–928 (2014). https://doi.org/10.1111/cen.12556CrossRefPubMed

I. Campi, D. Covelli, C. Moran, L. Fugazzola, C. Cacciatore, F. Orlandi, G. Gallone, K. Chatterjee, P. Beck-Peccoz, L. Persani, The differential diagnosis of discrepant thyroid function tests: insistent pitfalls and updated flow-chart based on a long-standing experience. Front. Endocrinol. (Lausanne) 11, 432 (2020). https://doi.org/10.3389/fendo.2020.00432CrossRefPubMed

P. Beck-Peccoz, A. Lania, A. Beckers, K. Chatterjee, J.-L. Wemeau. J.E.T.J.: 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. 2(2), 76–82 (2013).

10.

E. Macchia, M. Gasperi, M. Lombardi, L. Morselli, A. Pinchera, G. GAcerbi, G. Rossi, E. Martino. J.J.O.E.I.: Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience. 32(9), 773–779 (2009).

11.

F. Brucker-Davis, E.H. Oldfield, M.C. Skarulis, J.L. Doppman, B.D. Weintraub. J.T.J.O.C.E., Metabolism: Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. 84(2), 476–486 (1999).

12.

K. Feingold, B. Anawalt, A. Boyce, G. Chrousos, W. de Herder, K. Dhatariya, K. Dungan, A. Grossman, J. Hershman, J. Hofland. J.E.: Thyrotropin-Secreting Pituitary Adenomas (2000).

13.

P. Beck-Peccoz, F.O. Brucker-Davis, L. Persani, R.C. Smallridge, B.D.J.E.R. Weintraub, Thyrotropin-secreting pituitary tumors 17(6), 610–638 (1996)

14.

C. Nilsson, S. Aboud, K. Karlen, B. Hejdeman, W. Urassa, G. Biberfeld, Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin. Vaccine Immunol. 15(4), 585–589 (2008). https://doi.org/10.1128/CVI.00161-07CrossRefPubMedPubMedCentral

15.

K.F. Schulz, D.G. Altman, D.J. Moher. J.O.P., pharmacotherapeutics: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. 1(2), 100–107 (2010).

16.

O. Koulouri, C. Moran, D. Halsall, K. Chatterjee, M. Gurnell, Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract. Res. Clin. Endocrinol. Metab. 27(6), 745–762 (2013). https://doi.org/10.1016/j.beem.2013.10.003CrossRefPubMedPubMedCentral

17.

K. Paczkowska, A. Otlewska, O. Loska, K. Kolačkov, M. Bolanowski, J. Daroszewski. J.E.P.: Laboratory interference in the thyroid function test. 71(6), 551–560 (2020).

18.

S. Mamanasiri, S. Yesil, A.M. Dumitrescu, X.-H. Liao, T. Demir, R.E. Weiss, S.J.T. Refetoff. J.O.C.E., Metabolism: Mosaicism of a thyroid hormone receptor-β gene mutation in resistance to thyroid hormone. 91(9), 3471–3477 (2006).

19.

P. Concolino, A. Costella, R.M. Paragliola, Mutational landscape of resistance to thyroid hormone beta (RTHbeta). Mol Diagn Ther 23(3), 353–368 (2019). https://doi.org/10.1007/s40291-019-00399-wCrossRefPubMed

20.

F. Illouz, C. Briet, D. Mirebeau-Prunier, N. Bouhours-Nouet, R. Coutant, P. Sibilia, P. Rodien, Cardiac complications of thyroid hormone resistance syndromes. Ann. Endocrinol. (Paris) 82(3-4), 167–169 (2021). https://doi.org/10.1016/j.ando.2020.03.008CrossRefPubMed

Titel: Can a novel drug dose be used for T3 suppression test?
verfasst von: Sedat Çetin
Mehmet Güven
Başak Bolayır
Mehmet Şimşek
Hikmet Soylu
Dilek Geneş
Nurettin Ay
Halit Diri
Publikationsdatum: 10.07.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03445-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Can a novel drug dose be used for T3 suppression test?